Confirmation of reported aspirin use in community studies: Utility of serum thromboxane B2 measurement

Nicole Dodge Zantek, Russell V. Luepker, Sue Duval, Karen Miller, Niki Oldenburg, Alan T. Hirsch

Research output: Contribution to journalArticlepeer-review

12 Scopus citations


Aspirin (ASA) is recommended for the prevention of cardiovascular disease; however, the compliance is low. Reported use may not reflect actual use. Serum thromboxane B2 (STxB2) measurement was evaluated to validate reported ASA use. Males aged 45 to 79 years and females aged 55 to 79 years completed a survey and STxB2 measurement (Thromboxane B 2 EIA Kit; Cayman Chemical, Ann Arbor, Michigan). The 107 patients were grouped by use of ASA (56 ASA+ and 51 ASA-) and possible interfering medications (INT) such as nonsteroidal anti-inflammatory drugs. The STxB 2 levels (ng/mL) were significantly lower in ASA users: ASA+ INT- 3.0 (0.7, 8.4), ASA+ INT+ 2.0 (0.8, 4.9), ASA- INT+ 176 (75, 390), and ASA- INT- 271 (199, 366). The INT use did not cause a significant difference in STxB 2 levels. A STxB2 cut point of 25 ng/mL had high sensitivity (94.1%) and specificity (91.1%) for ASA use. The STxB2 was a reliable marker of ASA use and could be used to confirm ASA exposure in population-based health studies.

Original languageEnglish (US)
Pages (from-to)385-392
Number of pages8
JournalClinical and Applied Thrombosis/Hemostasis
Issue number4
StatePublished - May 2014


  • aspirin
  • cardiovascular prevention
  • compliance
  • nonsteroidal anti-inflammatory drug

Fingerprint Dive into the research topics of 'Confirmation of reported aspirin use in community studies: Utility of serum thromboxane B<sub>2</sub> measurement'. Together they form a unique fingerprint.

Cite this